SVF
Level A· Stronger Clinical EvidenceSystematic Review

Exosomes and Hair Regeneration: A Systematic Review of Clinical Evidence Across Alopecia Types and Exosome Sources.

Al Ameer MA., Alnajim AT., Al Ameer A., Alsalman Z., Al Ameer GA., Alnajim ST.

Systematic Review on Hair Loss, Hair Regeneration, published in Clin Cosmet Investig Dermatol (2025) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Systematic Review
Journal
Clin Cosmet Investig Dermatol (2025)
Country
New Zealand
Reported sample size
—
PMID
40955427
DOI
10.2147/CCID.S543451

Abstract (original English)

Mesenchymal stem cell (MSC)-derived exosomes are recognized a promising cell-free therapy for alopecia. These nano-vesicles facilitate intercellular communication and contain a variety of bioactive molecules that can potentially stimulate hair follicle regeneration. However, the safety and efficacy of exosome therapy for alopecia remains to be determined. This systematic analysis aimed to determine the clinical safety and effectiveness of exosome therapy for hair growth, particularly androgenetic alopecia (AGA) and other forms of hair loss. Systematic searches were conducted on PubMed, Scopus, and Embase databases to find clinical studies published from inception until 10th May 2025 that explored exosome-based interventions for hair loss. Eleven studies included: two RCTs, three retrospective studies, three prospective single-arm studies, one case series, and two case reports. Extracted data included method of preparation, outcomes of hair regrowth (density, thickness, patient satisfaction), and side effects. Quality of evidence was assessed using the Oxford Centre for Evidence-Based Medicine (OCEBM) levels and risk of bias tools (RoB 2 and ROBINS-I). All the studies included demonstrated improvements in at least one hair parameter, with MSC-derived exosomes from adipose tissue, placenta, hair follicles, bone marrow, foreskin, and umbilical cord having substantial increases in

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
Hair & ScalpHair LossHair Regeneration
View on PubMedDOI

Related research